light-mediated

Optovin is a TRPA1 activator, which is reversibly photoactivated.

C-MS023 is a photoactivatable prodrug of MS023, designed to achieve spatiotemporal inhibition of Histone Arginine Asymmetric Dimethylation. It specifically inhibits PRMT6-mediated asymmetric dimethylation of H3 Arginine 2 (H3R2me2a) with an IC50 of approximately 0.2224 μM. The photolysis of C-MS023 can be triggered by exposure to 420 nm visible light, releasing MS023, which effectively downregulates histone arginine asymmetric dimethylation and transcriptional activities related to DNA replication.

IgG has four forms, provides the majority of antibody-based immunity against invading pathogens. The only antibody capable of crossing the placenta to give passive immunity to the fetus. Eliminates pathogens in the early stages of B cell-mediated (humoral

Porfimer sodium is t he sodium salt of a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units with photodynamic activity. Absorbed selectively by tumor cells, porfimer produces oxygen radicals after activation by 630 nm w

Quisovalimab is a fully human monoclonal antibody that specifically binds to and neutralizes LIGHT(TNFSF14), a member of tumor necrosis factor superfamily, thus blocking its interaction with the receptor and inhibiting T cell-related inflammatory response. Quisovalimab has been used to study the inflammatory pathway mediated by LIGHT, and it has potential therapeutic value in COVID-19-related acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS).

Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal immunoglobulin G1 (IgG1) antibody specifically targeting the serum amyloid P component (SAP), a protein universally found in all types of amyloid deposits, and it possesses potential anti-amyloid activity by triggering an immunotherapeutic mechanism for the clearance of amyloid fibrils through macrophage-mediated phagocytosis, which can be applied in the research of amyloid light-chain (AL) amyloidosis and other systemic amyloid diseases.

CaMKIIα-PHOTAC is a photochemically targeted chimera (PHOTAC) that specifically targets Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα), facilitating its ubiquitination and subsequent proteasome-mediated degradation when exposed to specific light wavelengths. Under illumination, CaMKIIα-PHOTAC diminishes synaptic functions and weakens evoked field excitatory postsynaptic potentials in the mouse hippocampus, impacting physiological responses and sustaining long-term potentiation and memory functions within dendritic domains [1].

Anti-ANGPT2 Antibody is a humanized monoclonal antibody expressed in CHO cells targeting Angiopoietin-2 (Ang2/ANGPT2). This product, featuring a huIgG1 heavy chain and a hukappa light chain, has a predicted molecular weight of 150 kDa. It binds specifically to Ang2 with high affinity, blocking its interaction with the Tie2 receptor. This blockade removes Ang2-mediated vascular destabilization signals, inhibiting vascular endothelial cell activation, angiogenesis, and vascular leakage.

HuGAL-F2 is a humanized monoclonal antibody targeting human basic fibroblast growth factor (bFGF/FGF2). FGF2 is a critical factor in tumor angiogenesis, exerting its effects by binding to and activating FGFRs, which possess receptor tyrosine kinase activity. HuGAL-F2 functions by specifically binding to and neutralizing extracellular FGF2, blocking its interaction with FGFRs and directly inhibiting endothelial cell proliferation, migration, and tube formation mediated by this pathway. Featuring a huIgG2 heavy chain and a hu-kappa light chain, this antibody is a significant tool for researching solid tumor angiogenesis and tissue fibrosis.

Anti-Amyloid Beta Antibody (CNTO 2125) is a recombinant humanized monoclonal antibody targeting human Amyloid Beta (Aβ/Amyloid Beta). Aβ is the core component of amyloid plaques in the Alzheimer's disease (AD) brain, generated from the cleavage of amyloid precursor protein (APP). CNTO 2125 specifically binds to Aβ with high affinity (e.g., EC50 ≈ 9.7 ng/mL), blocking the aggregation of Aβ monomers and promoting the clearance of existing plaques. By targeting the Aβ cascade, this antibody has the potential to protect neurons from Aβ-mediated neurotoxic damage, serving as a critical tool for researching the pathogenesis and immunotherapy of Alzheimer's disease. This antibody features a huIgG1 heavy chain and a hu-kappa light chain.

Anti-Haptoglobin Antibody is a humanized monoclonal antibody expressed in CHO cells targeting Haptoglobin (HP). This product, featuring a huIgG1 heavy chain and a hukappa light chain, has a predicted molecular weight of 150 kDa. It binds specifically to Haptoglobin with high affinity, blocking its interaction with free hemoglobin (Hb) or damage-associated molecular patterns (DAMPs, such as HMGB1). By interfering with HP-mediated ligand clearance mechanisms (e.g., the CD163 pathway), the antibody inhibits its anti-inflammatory or immunomodulatory functions. It serves as an important pharmacological tool for researching hemolytic diseases, acute phase responses, and the tumor immune microenvironment.

APX-007 is a human monoclonal antibody expressed in CHO cells that specifically targets IL-6 Receptor alpha (IL-6Rα/CD126). It features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight of approximately 150 kDa. By binding to IL-6Rα, APX-007 blocks the interaction between IL-6 and its receptor, thereby inhibiting both classical and trans-signaling pathways mediated by IL-6 and suppressing downstream inflammatory cascades. This antibody is a valuable tool for research into autoimmune diseases and chronic inflammation. The recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).

Rat IgG2a kappa, Isotype Control is a rat-derived IgG2a κ isotype control monoclonal antibody, suitable for use as an experimental control for Rat IgG2a κ antibodies.

NGM-621 is a CHO-expressed fully human monoclonal antibody targeting Complement C3, composed of a huIgG1 heavy chain and huκ light chain with a predicted molecular weight of 149.04 kDa. NGM-621 is used as a precise biological reagent for investigating complement-mediated inflammation and immune regulation mechanisms.

Nocarnickelamides B (Compound 2) is a linear peptide and an inhibitor of ROCK1/2. It exhibits dual inhibitory activity against ROCK1 and ROCK2, with IC50 values of 14.9 μM and 21.9 μM, respectively. This compound binds to the ATP binding site and inhibits ROCK-mediated cytoskeletal contraction markers, such as myosin light chain activation. Nocarnickelamides B can be utilized in glaucoma research.